CXCR4 and hematologic disorder: Furthermore, labeling a CXCR4 ligand with an alpha-emitter for ERT might present a breakthrough in hematologic malignancies, as the higher energy transfer would lead to more effective destruction of cancer and cancer-supporting cells.